Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 3063

AbstractMaterial and MethodsResultsDiscussionConclusionReferencesDOI and Others
Article in PDF How to Cite Citation Manager Readers' Comments (0) Audio Visual Article Statistics Link to PUBMED Print this Article Send to a Friend
Advertisers Access Statistics Resources

Dr Mohan Z Mani

"Thank you very much for having published my article in record time.I would like to compliment you and your entire staff for your promptness, courtesy, and willingness to be customer friendly, which is quite unusual.I was given your reference by a colleague in pathology,and was able to directly phone your editorial office for clarifications.I would particularly like to thank the publication managers and the Assistant Editor who were following up my article. I would also like to thank you for adjusting the money I paid initially into payment for my modified article,and refunding the balance.
I wish all success to your journal and look forward to sending you any suitable similar article in future"



Dr Mohan Z Mani,
Professor & Head,
Department of Dermatolgy,
Believers Church Medical College,
Thiruvalla, Kerala
On Sep 2018




Prof. Somashekhar Nimbalkar

"Over the last few years, we have published our research regularly in Journal of Clinical and Diagnostic Research. Having published in more than 20 high impact journals over the last five years including several high impact ones and reviewing articles for even more journals across my fields of interest, we value our published work in JCDR for their high standards in publishing scientific articles. The ease of submission, the rapid reviews in under a month, the high quality of their reviewers and keen attention to the final process of proofs and publication, ensure that there are no mistakes in the final article. We have been asked clarifications on several occasions and have been happy to provide them and it exemplifies the commitment to quality of the team at JCDR."



Prof. Somashekhar Nimbalkar
Head, Department of Pediatrics, Pramukhswami Medical College, Karamsad
Chairman, Research Group, Charutar Arogya Mandal, Karamsad
National Joint Coordinator - Advanced IAP NNF NRP Program
Ex-Member, Governing Body, National Neonatology Forum, New Delhi
Ex-President - National Neonatology Forum Gujarat State Chapter
Department of Pediatrics, Pramukhswami Medical College, Karamsad, Anand, Gujarat.
On Sep 2018




Dr. Kalyani R

"Journal of Clinical and Diagnostic Research is at present a well-known Indian originated scientific journal which started with a humble beginning. I have been associated with this journal since many years. I appreciate the Editor, Dr. Hemant Jain, for his constant effort in bringing up this journal to the present status right from the scratch. The journal is multidisciplinary. It encourages in publishing the scientific articles from postgraduates and also the beginners who start their career. At the same time the journal also caters for the high quality articles from specialty and super-specialty researchers. Hence it provides a platform for the scientist and researchers to publish. The other aspect of it is, the readers get the information regarding the most recent developments in science which can be used for teaching, research, treating patients and to some extent take preventive measures against certain diseases. The journal is contributing immensely to the society at national and international level."



Dr Kalyani R
Professor and Head
Department of Pathology
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research , Kolar, Karnataka
On Sep 2018




Dr. Saumya Navit

"As a peer-reviewed journal, the Journal of Clinical and Diagnostic Research provides an opportunity to researchers, scientists and budding professionals to explore the developments in the field of medicine and dentistry and their varied specialities, thus extending our view on biological diversities of living species in relation to medicine.
‘Knowledge is treasure of a wise man.’ The free access of this journal provides an immense scope of learning for the both the old and the young in field of medicine and dentistry as well. The multidisciplinary nature of the journal makes it a better platform to absorb all that is being researched and developed. The publication process is systematic and professional. Online submission, publication and peer reviewing makes it a user-friendly journal.
As an experienced dentist and an academician, I proudly recommend this journal to the dental fraternity as a good quality open access platform for rapid communication of their cutting-edge research progress and discovery.
I wish JCDR a great success and I hope that journal will soar higher with the passing time."



Dr Saumya Navit
Professor and Head
Department of Pediatric Dentistry
Saraswati Dental College
Lucknow
On Sep 2018




Dr. Arunava Biswas

"My sincere attachment with JCDR as an author as well as reviewer is a learning experience . Their systematic approach in publication of article in various categories is really praiseworthy.
Their prompt and timely response to review's query and the manner in which they have set the reviewing process helps in extracting the best possible scientific writings for publication.
It's a honour and pride to be a part of the JCDR team. My very best wishes to JCDR and hope it will sparkle up above the sky as a high indexed journal in near future."



Dr. Arunava Biswas
MD, DM (Clinical Pharmacology)
Assistant Professor
Department of Pharmacology
Calcutta National Medical College & Hospital , Kolkata




Dr. C.S. Ramesh Babu
" Journal of Clinical and Diagnostic Research (JCDR) is a multi-specialty medical and dental journal publishing high quality research articles in almost all branches of medicine. The quality of printing of figures and tables is excellent and comparable to any International journal. An added advantage is nominal publication charges and monthly issue of the journal and more chances of an article being accepted for publication. Moreover being a multi-specialty journal an article concerning a particular specialty has a wider reach of readers of other related specialties also. As an author and reviewer for several years I find this Journal most suitable and highly recommend this Journal."
Best regards,
C.S. Ramesh Babu,
Associate Professor of Anatomy,
Muzaffarnagar Medical College,
Muzaffarnagar.
On Aug 2018




Dr. Arundhathi. S
"Journal of Clinical and Diagnostic Research (JCDR) is a reputed peer reviewed journal and is constantly involved in publishing high quality research articles related to medicine. Its been a great pleasure to be associated with this esteemed journal as a reviewer and as an author for a couple of years. The editorial board consists of many dedicated and reputed experts as its members and they are doing an appreciable work in guiding budding researchers. JCDR is doing a commendable job in scientific research by promoting excellent quality research & review articles and case reports & series. The reviewers provide appropriate suggestions that improve the quality of articles. I strongly recommend my fraternity to encourage JCDR by contributing their valuable research work in this widely accepted, user friendly journal. I hope my collaboration with JCDR will continue for a long time".



Dr. Arundhathi. S
MBBS, MD (Pathology),
Sanjay Gandhi institute of trauma and orthopedics,
Bengaluru.
On Aug 2018




Dr. Mamta Gupta,
"It gives me great pleasure to be associated with JCDR, since last 2-3 years. Since then I have authored, co-authored and reviewed about 25 articles in JCDR. I thank JCDR for giving me an opportunity to improve my own skills as an author and a reviewer.
It 's a multispecialty journal, publishing high quality articles. It gives a platform to the authors to publish their research work which can be available for everyone across the globe to read. The best thing about JCDR is that the full articles of all medical specialties are available as pdf/html for reading free of cost or without institutional subscription, which is not there for other journals. For those who have problem in writing manuscript or do statistical work, JCDR comes for their rescue.
The journal has a monthly publication and the articles are published quite fast. In time compared to other journals. The on-line first publication is also a great advantage and facility to review one's own articles before going to print. The response to any query and permission if required, is quite fast; this is quite commendable. I have a very good experience about seeking quick permission for quoting a photograph (Fig.) from a JCDR article for my chapter authored in an E book. I never thought it would be so easy. No hassles.
Reviewing articles is no less a pain staking process and requires in depth perception, knowledge about the topic for review. It requires time and concentration, yet I enjoy doing it. The JCDR website especially for the reviewers is quite user friendly. My suggestions for improving the journal is, more strict review process, so that only high quality articles are published. I find a a good number of articles in Obst. Gynae, hence, a new journal for this specialty titled JCDR-OG can be started. May be a bimonthly or quarterly publication to begin with. Only selected articles should find a place in it.
An yearly reward for the best article authored can also incentivize the authors. Though the process of finding the best article will be not be very easy. I do not know how reviewing process can be improved. If an article is being reviewed by two reviewers, then opinion of one can be communicated to the other or the final opinion of the editor can be communicated to the reviewer if requested for. This will help one’s reviewing skills.
My best wishes to Dr. Hemant Jain and all the editorial staff of JCDR for their untiring efforts to bring out this journal. I strongly recommend medical fraternity to publish their valuable research work in this esteemed journal, JCDR".



Dr. Mamta Gupta
Consultant
(Ex HOD Obs &Gynae, Hindu Rao Hospital and associated NDMC Medical College, Delhi)
Aug 2018




Dr. Rajendra Kumar Ghritlaharey

"I wish to thank Dr. Hemant Jain, Editor-in-Chief Journal of Clinical and Diagnostic Research (JCDR), for asking me to write up few words.
Writing is the representation of language in a textual medium i e; into the words and sentences on paper. Quality medical manuscript writing in particular, demands not only a high-quality research, but also requires accurate and concise communication of findings and conclusions, with adherence to particular journal guidelines. In medical field whether working in teaching, private, or in corporate institution, everyone wants to excel in his / her own field and get recognised by making manuscripts publication.


Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."



Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
E-mail: drrajendrak1@rediffmail.com
On May 11,2011




Dr. Shankar P.R.

"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."



Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
E-mail: ravi.dr.shankar@gmail.com
On April 2011
Anuradha

Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.


Dr. Anuradha
E-mail: anuradha2nittur@gmail.com
On Jan 2020

Important Notice

Original article / research
Year : 2024 | Month : July | Volume : 18 | Issue : 7 | Page : EC11 - EC16 Full Version

A Retrospective Cross-sectional Analysis of Renal Complications in Association with Cancer: Insights from 120 Autopsies


Published: July 1, 2024 | DOI: https://doi.org/10.7860/JCDR/2024/63309.19585
Gwendolyn Fernandes, Gloria Khumanthem, Sharada Datar, Kasturi Khot

1. Additional Professor, Department of Pathology, G.S. Medical College and K.E.M. Hospital, Mumbai, Maharashtra, India. 2. Fellow, Department of Pathology, G.S. Medical College and K.E.M. Hospital, Mumbai, Maharashtra, India. 3. Ex-Fellow, Department of Pathology, G.S. Medical College and K.E.M. Hospital, Mumbai, Maharashtra, India. 4. Junior Resident, Department of Pathology, G.S. Medical College and K.E.M. Hospital, Mumbai, Maharashtra, India.

Correspondence Address :
Gwendolyn Fernandes,
C-802, Swayam, Poonam Gardens, Off Mira- Bhayander Road, Mumbai-401107, Maharashtra, India.
E-mail: drgwenfern@yahoo.co.in

Abstract

Introduction: Kidney diseases frequently complicate cancer and its treatment, contributing to both morbidity and mortality. Malignancies can give rise to various kidney issues, such as glomerulonephritis and Chronic Kidney Disease (CKD). This association operates bidirectionally, with patients experiencing the development of renal diseases due to cancer, and CKD predisposing to cancer. Furthermore, nephrotoxicity induced by chemotherapy can result in Acute Tubular Injury (ATI) and necrosis, imposing limitations on its application.

Aim: To evaluate the spectrum of renal pathology in autopsies of malignancies.

Materials and Methods: This was a retrospective cross-sectional study of complete autopsies of all cases of malignancies performed in the Department of Pathology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India. The study was carried out over a 5-year period from January 2015 to December 2019. Analysis of cases with respect to demographics, type of primary malignancy, gross and microscopic features, and the final cause of death was conducted. These findings were meticulously tabulated, with frequencies and percentages calculated for each category.

Results: A total of 4392 autopsies were conducted throughout the study period, with 120 of them revealing the presence of malignancies. A total of 38 (31.6%) malignancies were diagnosed for the first time at autopsy. The commonest renal findings on gross were scars (superficial and deep) seen in 40 (33.33%), followed by cortical cysts in 25 (20.83%), granular contracted kidney in 15 (12.50%), mass lesions in 7 (5.83%), abscesses in 7 (5.83%), and swollen, oedematous kidneys in 6 (5%) autopsies. The most frequent renal pathology on microscopy were infective lesions seen in 43 (35.83%), Acute Tubular Necrosis (ATN) in 32 (26.66%), ATI in 30 (25%), followed by malignancies- primary and secondary in 11 (9.16%), tubular casts in 6 (5%), etc. Rare findings included membranous glomerulonephritis and Tumour Lysis Syndrome (TLS) (Acute urate nephropathy) in 1 (0.83%) each. The TLS case had classic histomorphological features of TLS, apart from laboratory parameters. Extensive deposits of uric acid crystals were seen obstructing the tubules as well as some of the glomeruli on microscopy.

Conclusion: In one-third of the cases, the malignancy was exclusively discovered during the autopsy. The study revealed a diverse array of lesions, encompassing pyelonephritis, ATN, primary and metastatic renal tumours, cast nephropathy, membranous glomerulonephritis, and TLS. One-fifth of the cases had end-stage renal disease (advanced renal disease). A significant number of the cases exhibited tumour masses within the kidneys. One-fifth of the cases had renal pathology contributing to the final cause of death, further highlighting the association between malignancies and renal pathology.

Keywords

Autopsy, Chemotherapy, Kidney disease, Malignancies, Postmortem

Kidney disease is known to occur in patients with malignancies and significantly contributes to both morbidity and mortality. Malignancies can give rise to various kidney issues and can impact the kidney in various ways. These include paraneoplastic nephropathies, nephrotoxic effects of chemotherapy and other medications, radiation, nephrectomies for renal cell carcinoma, obstruction or compression, tumour infiltration of the renal parenchyma, and underlying conditions like diabetes and hypertension (1). Patients with malignancies exhibit a broad spectrum of renal pathology, encompassing conditions from ATI to CKD and even TLS. Therefore, renal pathology in cancer patients may arise from both the malignancy itself and the administration of various chemotherapy and immunosuppressive drugs during treatment. This association operates bidirectionally, as patients with cancer can develop renal diseases, while CKD can also predispose individuals to cancer.

Different malignancies have been found to occur in different stages of CKD. The prevalence of estimated Glomerular Filtration Rate (eGFR) of <60 mL/min per 1.73 m2 in cancer patients is estimated to be 12-25% (2). CKD stage 5 is associated with a higher risk of developing cancers of the kidney and urinary bladder, as well as infection-associated malignancies such as carcinoma of the cervix, carcinoma of the lung, and liver malignancies due to immunosuppression. CKD stage 3 in men is known to cause an elevated risk of cancers of the urinary tract (2).

Acute Kidney Injury (AKI), proteinuria, and electrolyte disturbances are the most frequent renal diseases following chemotherapy and targeted therapies. Almost 50% of patients with multiple myeloma have AKI at presentation, and 10% required dialysis (3). Cancer-associated AKI is common and associated with CKD, diabetes, and the concomitant use of diuretics with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (4). Hence, the aim of the study was to evaluate the spectrum of renal pathology in autopsies of malignancies, as well as to assess the number of autopsies where renal pathology contributed significantly to the final cause of death. And the objective was to investigate the prevalence and types of renal pathology associated with different types of malignancies.

Material and Methods

This is a retrospective cross-sectional study of complete autopsies of all cases of malignancies performed in the Department of Pathology at Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India. The study was carried out over a 5-year period from January 2015 to December 2019. During this period, 4392 autopsies were performed.

Inclusion and Exclusion criteria: Complete autopsies, encompassing both pathological and medicolegal cases of all age groups with an Antemortem diagnosis or postmortem diagnosis of malignancy, were included in the study. Partial autopsies and those without a diagnosis of malignancy were excluded.

Study Procedure

The clinical details of these autopsies were extracted from the deceased case files, which are routinely transmitted along with the body for postmortem examination. To gain insight into the ante-mortem kidney function of the cases, serum creatinine (Cr) and Blood Urea Nitrogen (BUN) levels were recorded from the case files. The normal range utilised as the reference was 0.7-1.2 mg/dL for Cr and 7-30 mg/dL for BUN. Every case was analysed with respect to demographics, the type of primary malignancy, gross, microscopy, Immunohistochemistry (IHC), and the final cause of death. IHC markers were done wherever required to make the diagnosis. The IHC markers used included epithelial markers such as Epithelial Membrane Antigen (EMA), Pan CK (Pan Cytokeratin), CK7, and CK20 aiding in the identification of epithelial cell characteristics. Hormonal markers crucial in assessing hormone receptor status comprised Oestrogen Receptor (ER), Progesterone Receptor (PR), and HER2Neu for breast carcinoma and Prostate Specific Antigen (PSA) for prostate carcinoma. Lymphoid markers encompassed Leukocyte Common Antigen (LCA), CD10, CD3, CD20, MPO (Myeloperoxidase), and CD38. Markers for neuroendocrine differentiation included Synaptophysin and Chromogranin. Additionally, markers such as Kappa and Lambda were utilised for the diagnosis of Myeloma and other light chain deposition diseases. MIB-1 labelling was done to assess the proliferative activity of the tumour cells. As this study was conducted in a government institute, IHC on every autopsy could not be done due to economic constraints and was done only in autopsies where it is essential for the diagnosis.

Statistical Analysis

Descriptive statistics were utilised in the form of mean, median, frequency, and percentages as needed.

Results

A total of 120 autopsies of malignancies were conducted over a 5-year period from 2015 to 2019. Of these, 51 (42.5%) patients belonged to the 4th to the 6th decade, while 39 (32.5%) patients were in their 6th to 8th decade. A total of 8 (6.67%) patients were under 20 years of age. A total of 66 (55%) were male and 44 (45%) were female, and the mean age was 52.48 years.

Among the 120 autopsies, 59 (49.15%) had completed chemotherapy or were in the process of chemotherapy at the time of death. A total of 35 (29%) did not receive chemotherapy, and it was not known whether 26 (22.03%) received any chemotherapy.

Serum creatinine levels were <1.3 mg/dL in 48 (40.18%) cases and >1.3 mg/dL in 52 (43.33%) cases. BUN levels were <20 mg/dL in 40 (33.89%) cases and >20 mg/dL in 54 (45.77%) cases. Of the diagnosed malignancies, 33 (29.66%) cases were from the gastrointestinal tract, 25 (18.6%) cases were from the hepatobiliary tract, and 11 (6.77%) cases were haematolymphoid malignancies (Table/Fig 1).

On gross examination, contracted granular kidneys (indicative of advanced renal disease) were observed in 15 (12.50%) cases. Scars, both superficial and deep, were present in 40 (33.33%) cases. Tumour deposits/mass lesions were identified in 7 (5.83%) cases (Table/Fig 2),(Table/Fig 3).

Microscopic examination revealed a spectrum of glomerular lesions, with membranous glomerulopathy observed in a case of colonic adenocarcinoma and segmental sclerotic lesions seen in a single case (Table/Fig 4)a-f. Glomerular hypercellularity was noted in 2 (1.66%) cases, but further evaluation through Immunofluorescence (IF) and Electron Microscopy (EM) could not be conducted in 3 cases due to economic constraints. A significant number (>75%) of globally sclerosed glomeruli (indicative of advanced renal disease) were seen in 25 (20.83%) cases, and thrombotic microangiopathy was identified in 3 (2.5%) of the autopsies (Table/Fig 5).

In tubulointerstitial lesions, acute pyelonephritis was observed in two cases. Chronic Pyelonephritis (CPN) was subcategorised into mild CPN in 23 cases, moderate CPN in seven cases, and severe CPN in six cases (Table/Fig 5). Extensive tuberculous pyelonephritis was seen in a single case, and abscesses were found in four cases. The presence of tuberculous pyelonephritis in this context may be linked to the immunosuppressed state commonly seen in cancer patients. A total of 43 (35.83%) cases were of infective aetiology (Table/Fig 5). A significant number of cases presented ATN in 32 (26.66%) cases, Acute Tubulointerstitial Nephritis (ATI) in 30 (25%) cases, and Tubular Atrophy-Interstitial Fibrosis (IFTA) in 12 (10%) cases (Table/Fig 5). A variety of tubular casts were observed in 6 (5%) cases, among which bile casts were seen in three cases, White Blood Cells (WBC) casts in two cases, and myeloma casts in a single case (Table/Fig 5),(Table/Fig 6)a-f. Vascular lesions were also common, with medial hypertrophy in 20 (16.66%) cases, hyaline arteriosclerosis in 14 (11.66%) cases, and infarcts observed in 2 (1.66%) cases. An unusual case of acute urate nephropathy (TLS) was noted in a case of T-cell acute lymphoblastic leukaemia. On gross examination, the kidneys appeared enlarged with map-like areas of tumour deposits (Table/Fig 7)a,b. Microscopic examination revealed more than 95% lymphoblasts on the peripheral blood smear. Additionally, the kidneys exhibited extensive infiltrates of lymphoblasts, with the renal tubules and glomeruli impacted by urate crystals (Table/Fig 8)a-c. Renal pathology significantly contributed to the cause of death in 23 (19.16%) cases, while the pathology of other organ systems led to the cause of death in 97 (80.83%) cases (Table/Fig 9). Renal pathology played a significant role in contributing directly or indirectly to the cause of death. Some indirect causes included severe CPN and renal abscess, which precipitated septicemia ultimately leading to death. Meanwhile, direct causes encompassed ATN and cast nephropathy, resulting in acute renal failure and subsequent death.

Discussion

A diverse array of renal pathologies is clinically observed and evident in patients with malignancies. These pathologies encompass a wide range, affecting all components of the kidney. They include renal parenchymal invasion, ATI, ATN, CKD, thrombotic microangiopathy, glomerular diseases, malignant obstructive uropathy, chronic tubulointerstitial nephritis, electrolyte disturbances, and nephrotoxic effects induced by anticancer drugs, including chemotherapy and immunotherapy (5),(6).

Out of the 120 autopsies of malignancy in the present study, 59 (49.15%) cases had received chemotherapy. Chemotherapy-induced kidney injury is becoming more prevalent with newer anticancer drugs that are being added to chemotherapy regimens. Gemcitabine, Mitomycin C, and antiangiogenesis drugs are known to cause TMA (7). Renal complications like focal segmental glomerulosclerosis have been associated with therapy by Interferons (IFN), pamidronate, and zoledronate, while minimal change disease has been linked to IFN. BRAF inhibitors, ALK inhibitors, and PD-1 inhibitors can cause acute interstitial nephritis (2),(8).

The most prevalent renal diseases in patients with malignancies are AKI and electrolyte disturbances (3). AKI and ATN were significant findings in the present study, with ATI observed in 30 (25%) cases and ATN in 32 (26.6%) cases, collectively accounting for more than 50% of our autopsy cases. Distinguishing ATI from postmortem degenerative changes becomes challenging, especially when the autopsy is delayed and conducted long after death. Therefore, the present study may reflect a higher incidence of ATI. Sepsis emerges as the leading cause of AKI in cancer patients. The use of anti-infectives in treating sepsis in critically-ill cancer patients can lead to nephrotoxicity and AKI. Co-morbidities such as CKD, congestive cardiac failure, hypertension, diabetes mellitus, and liver disease also contribute to the occurrence of AKI (4). Glomerular diseases can arise either as a paraneoplastic process or as a consequence of chemotherapy (9). Among glomerular lesions, a significant number of globally sclerosed glomeruli (indicative of advanced renal disease) were observed in 25 cases (20.83%). Glomerular hypercellularity was noted in a single case related to adenocarcinoma of the gastrointestinal tract. Additionally, a case of membranous glomerulopathy was identified in association with adenocarcinoma of the colon. Glomerular pathology manifests across various malignant diseases, with membranous glomerulonephritis being the most common, often linked to solid cancers. The precise incidence of malignancy with membranous nephropathy remains unknown, though several studies report a prevalence ranging from 1% to 22%. Minimal change disease is predominantly associated with Hodgkin disease, while membranoproliferative glomerulonephritis is linked to chronic lymphocytic leukaemia (8),(10).

Three of the autopsies had TMA as a terminal event that led to death. TMA is a complication that can develop directly from the underlying malignancy or more often from anticancer therapy (11). In the present study, authors encountered three noteworthy autopsies, one of which involved a young male diagnosed with plasma cell myeloma during the autopsy. The 33-year-old patient presented with lower back pain and progressive weakness in the lower limbs over the past two months. An Magnetic Resonance Imaging (MRI) of the spine revealed a collapse of the D7 and D10 vertebral bodies, along with a large paravertebral soft-tissue mass. Positron Emission Tomography-computed Tomography scan (PET CT) scans indicated multiple osteolytic lesions throughout the entire skeleton. Autopsy findings in the kidneys revealed classic fracture casts and extensive malignant plasma cell infiltrates, confirmed as CD 68, Kappa, and EMA positive through IHC. The final diagnosis at autopsy was Multiple Myeloma with predominantly extraosseous involvement and cast nephropathy (Table/Fig 6).

The second distinctive case involved a 26-year-old pregnant patient who presented with fever and chills persisting for three weeks, accompanied by a dry cough and dyspnoea for one week, along with AKI. Further investigations revealed hypophosphatemia and hyperuricemia. A peripheral smear indicated a total count of 96,000 cells/cumm with 67% lymphoblasts. Autopsy findings demonstrated extensive infiltrates of lymphoblasts in the kidneys, along with abundant urate crystals impacting the renal tubules and Bowman’s space. A conclusive diagnosis of T-cell acute lymphoblastic leukaemia with multiorgan dissemination and acute urate nephropathy (TLS) was established (Table/Fig 7),(Table/Fig 8).

The third case involved a 23-year-old primigravida at 29 weeks gestation with a diagnosed bilateral large ovarian tumour, identified on ultrasonography. She presented at the tertiary care centre with severe abdominal pain, backache, and leaking per vagina. Physical examination revealed an oedematous abdominal wall, a gravid uterus of 34 weeks size, and tumours that could not be individually palpated. Despite these complications, she underwent a normal vaginal delivery, giving birth to a live female foetus weighing 1.6 kg. Unfortunately, she developed postpartum septicemia and pulmonary thromboembolism, leading to her demise. Postmortem examination revealed a large Krukenberg tumour in the right ovary measuring 40x26x14 cm and weighing 2 kg, along with a tumour in the left ovary measuring 20x10x6 cm and weighing 600 gm. Additionally, the sigmoid colon exhibited a 2x1 cm signet ring cell adenocarcinoma with peritoneal metastasis. IHC revealed positive CK and EMA results, while AFP and CD10 were negative. The bilateral kidneys were normal on gross and microscopy and probably remained so since the duration of the malignancy was only two months.

Two autopsies revealed an unknown primary source of malignancy; one of a 45-year-old female with disseminated poorly-differentiated adenocarcinoma and the other of a 65-year-old male with disseminated squamous cell carcinoma. Despite an extensive review of the literature, authors did not find any similar studies on renal pathology in autopsies of malignancy. In the current study, 38 (31.67%) malignancies were diagnosed for the first time only at autopsy. A study by Furia LD titled “The value of necropsy in oncology” reported major discordances between clinical and postmortem findings in 34 (33%) out of the 102 patients in their study (12).

The AKI and ATN were significant findings in the present study, with ATI observed in 30 (25%) and ATN in 32 (26.6%) of cases, collectively amounting to more than 50% of the autopsy cases. The incidence of AKI in cancer patients is reported to reach up to 12% by Salahudeen A et al., (13). The rate of AKI among critically-ill cancer patients varies from 12% to 49%, with 9-32% of patients requiring renal replacement therapy (14).

In a Danish study involving 37,257 cancer patients, the incidence of AKI was reported as 17.5% according to the RIFLE criteria (Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease) (15),(16),(17),(18). This study, representing the largest cohort of Danish cancer patients, revealed varying rates of AKI in specific cancer types: 44% in kidney cancers, 33% in myeloma, 31.8% in liver cancer, and 27.5% in leukaemia (14). In the present study, 20 autopsies (16.66%) revealed significant global sclerosis, indicating advanced renal disease. A study conducted by Ciorcan M et al., demonstrated a comparable prevalence of CKD, with 12.27% after the first year of follow-up and 13.42% after the second year, closely aligning with the present findings (19).

Limitation(s)

Limitations of the present study included economic constraints and resource limitations inherent in a government hospital setting. The unavailability of extensive immunohistochemical markers, IF, and EM posed additional challenges for detailed investigations. Furthermore, being an autopsy study, the absence of detailed clinical history, drug history, and antemortem laboratory details were a limitation. Postmortem changes also affected the pathological examination, introducing further complexity to the analysis.

Conclusion

The present study provides valuable insights into the complex interplay between renal complications and cancer. Notably, a significant proportion of malignancies were diagnosed for the first time through this comprehensive autopsy investigation, highlighting the importance of thorough postmortem examinations. The study emphasises the importance of incorporating renal assessment and management into the holistic care of cancer patients. By recognising and addressing renal complications early in the course of cancer treatment, healthcare providers can potentially mitigate morbidity and improve patient outcomes. Moving forward, these findings advocate for a tailored approach to oncology management that prioritises the identification and management of renal pathologies, ultimately contributing to improved patient care and outcomes.

References

1.
Cosmai L, Porta C, Gallieni M. Chapter 13: CKD as a complication of cancer. Onco- Nephrology Curriculum. American Society of Nephrology. Available from: https:// www.asn-online.org/education/distancelearning/curricula/onco/Chapter13.pdf.
2.
Porta C, Bamias A, Danesh FR, De?bska Slizie A, Gallieni M, Gertz MA, et al. KDIGO Controversies Conference on onco-nephrology: Understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. Kidney International. 2020;98(5):1108-19. [crossref][PubMed]
3.
Lahoti A, Humphreys BD. AKI associated with malignancies. Onconephrology Curriculum. 2016.
4.
Kitchlu A, McArthur E, Amir E. Acute kidney injury in patients receiving systemic treatment for cancer: A population based cohort study. J Natl Cancer Inst. 2019;111(7):727-36. [crossref][PubMed]
5.
Rosner M, Jhaveri K, McMahon B, Perazella MA. Onconephrology: The intersections between the kidney and cancer. CA: A Cancer Journal for Clinicians. 2021;71(1):47-77. [crossref][PubMed]
6.
Perazella M. Onco-nephrology: Renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol. 2012;7(10):1713-21. [crossref][PubMed]
7.
Nicolaysen A. Nephrotoxic chemotherapy agents: Old and new. Advanced Chronic Kidney Diseases. 2020;27(1):38-49. [crossref][PubMed]
8.
Francisco A, Macia M, Alonso F. Onco-Nephrology: Cancer, chemotherapy and kidney. Nefrologia. 2019;39(5):473-81. [crossref][PubMed]
9.
Bacchetta J, Juillard L, Cochat P, Droz J-P. Paraneoplastic glomerular diseases and malignancies. Critical Review in Oncology/Hematology. 2009;70(1):39-58. [crossref][PubMed]
10.
Jhaveri KD, Shah HH, Calderon K, Campenot ES, Radhakrishnan J. Glomerular diseases seen with cancer and chemotherapy: A narrarive review. Kidney Int. 2013;84(1):34-44. [crossref][PubMed]
11.
Izzedine H, Perazella M. Thrombotic microangiopathy, cancer, and cancer drugs. American Journal of Kidney Diseases. 2015;66(5):857-68. [crossref][PubMed]
12.
Furia LD. The value of necropsy in oncology. Eur J Cancer. 1991;27(5):559-61 [crossref][PubMed]
13.
Salahudeen A, Doshi S, Pawar T. Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer centre. American Society of Nephrology. 2013;8(3):347-54. [crossref][PubMed]
14.
Christiansen CF, Johansen MB, Langeberg WJ, Fryzek JP, Sorensen HT. Incidence of acute kidney injury in cancer patients: A Danish population-based cohort study. Eur J Intern Med. 2011;22(4):399-406. [crossref][PubMed]
15.
Darmon M, Ciroldi M, Thiery G, Schlemmer B, Azoulay E. Clinical review: Specific aspects of acute renal failure in cancer patients. Critical Care. 2006;10(2):211. [crossref][PubMed]
16.
Joannidis M, Metnitz PG. Epidemiology and natural history of acute renal failure in the ICU. Critical Care Clin. 2005;21(2):239-49. [crossref][PubMed]
17.
Lameire N, Van Biesen W, Vanholder R. The changing epidemiology of acute renal failure. Nat Clin Pract Nephrol. 2006;2(7):364-77. [crossref][PubMed]
18.
Lameire N, Van Biesen W, Vanholder R. Acute renal problems in the critically ill cancer patient. Curr Opin Crit Care. 2008;14(6):635-46. [crossref][PubMed]
19.
Ciorcan M, Chisavu L, Mihaescu A, Gadalean F, Bob FR, Negru S, et al. Chronic kidney disease in cancer patients, the analysis of a large oncology database from Eastern Europe. Plos One. 2022;17(6):e0265930.[crossref][PubMed]

DOI and Others

DOI: 10.7860/JCDR/2024/63309.19585

Date of Submission: Feb 06, 2023
Date of Peer Review: May 10, 2023
Date of Acceptance: May 13, 2024
Date of Publishing: Jul 01, 2024

AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was Ethics Committee Approval obtained for this study? Yes
• Was informed consent obtained from the subjects involved in the study? Yes
• For any images presented appropriate consent has been obtained from the subjects. Yes

PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Feb 10, 2023
• Manual Googling: May 20, 2023
• iThenticate Software: May 11, 2024 (5%)

ETYMOLOGY: Author Origin

EMENDATIONS: 7

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2017: 134.54
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • Embase
  • EBSCOhost
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)
  • www.omnimedicalsearch.com